Search Results | Diabetes Care | American Diabetes Association

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Relation of Change or Substitution of Low- and No-Calorie Sweetened Beverages With Cardiometabolic Outcomes: A Systematic Review and Meta-analysis of Prospective Cohort Studies

Jennifer J. Lee, Tauseef A. Khan, Nema McGlynn, Vasanti S. Malik, James O. Hill, Lawrence A. Leiter, Per Bendix Jeppesen, Dario Rahelić, Hana Kahleová, Jordi Salas-Salvadó, Cyril W.C. Kendall, John L. Sievenpiper

Diabetes Care 2022;45(8):1917–1930

DOI: https://doi.org/10.2337/dc21-2130

Published: 26 July 2022

View article

Journal Articles

Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58

Ahmed A. Kolkailah, Stephen D. Wiviott, Itamar Raz, Sabina A. Murphy, Ofri Mosenzon, Deepak L. Bhatt, Lawrence A. Leiter, John P.H. Wilding, Ingrid Gause-Nilsson, Marc S. Sabatine, Darren K. McGuire

Diabetes Care 2022;45(2):e27–e29

DOI: https://doi.org/10.2337/dc21-1668

Published: 17 January 2022

View article

Journal Articles

Association of Baseline HbA_1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58

Avivit Cahn, Stephen D. Wiviott, Ofri Mosenzon, Erica L. Goodrich, Sabina A. Murphy, Ilan Yanuv, Aliza Rozenberg, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P.H. Wilding, Ingrid A.M. Gause-Nilsson, Anna Maria Langkilde, Marc S. Sabatine, Itamar Raz

Diabetes Care 2022;45(4):938–946

DOI: https://doi.org/10.2337/dc21-1744

Published: 11 January 2022

View article

Journal Articles

A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes

David D. Berg, Stephen D. Wiviott, Benjamin M. Scirica, Thomas A. Zelniker, Erica L. Goodrich, Petr Jarolim, Ofri Mosenzon, Avivit Cahn, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P.H. Wilding, Per Johanson, Anna Maria Langkilde, Itamar Raz, Eugene Braunwald, Marc S. Sabatine, David A. Morrow

Diabetes Care 2021;44(11):2573–2581

DOI: https://doi.org/10.2337/dc21-1170

Published: 17 September 2021

View article

Journal Articles

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58

Diabetes Care 2021;44(8):1805–1815

DOI: https://doi.org/10.2337/dc21-0076

Published: 11 August 2021

View article

Journal Articles

Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58

Avivit Cahn, Itamar Raz, Lawrence A. Leiter, Ofri Mosenzon, Sabina A. Murphy, Erica L. Goodrich, Ilan Yanuv, Aliza Rozenberg, Deepak L. Bhatt, Darren K. McGuire, John P.H. Wilding, Ingrid A.M. Gause-Nilsson, Anna Maria Langkilde, Marc S. Sabatine, Stephen D. Wiviott

Diabetes Care 2021;44(5):1159–1167

DOI: https://doi.org/10.2337/dc20-2492

Published: 02 March 2021

View article

Journal Articles

A Lesson From 2020: Public Health Matters for Both COVID-19 and Diabetes

Matthew C. Riddle, George Bakris, Lawrence Blonde, Andrew J.M. Boulton, David D’Alessio, Linda A. DiMeglio, Linda Gonder-Frederick, Korey K. Hood, Frank B. Hu, Steven E. Kahn, Sanjay Kaul, Lawrence A. Leiter, Robert G. Moses, Stephen S. Rich, Julio Rosenstock, Judith Wylie-Rosett

Diabetes Care 2021;44(1):8–10

DOI: https://doi.org/10.2337/dci20-0071

Published: 14 December 2020

View article

Journal Articles

Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease

Gregory G. Schwartz, Lawrence A. Leiter, Christie M. Ballantyne, Philip J. Barter, Donald M. Black, David Kallend, Fouzia Laghrissi-Thode, Eran Leitersdorf, John J.V. McMurray, Stephen J. Nicholls, Anders G. Olsson, David Preiss, Prediman K. Shah, Jean-Claude Tardif, John Kittelson

Diabetes Care 2020;43(5):1077–1084

DOI: https://doi.org/10.2337/dc19-2204

Published: 06 March 2020

View article

Includes: Supplementary data

Journal Articles

Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study

Avivit Cahn, Ofri Mosenzon, Stephen D. Wiviott, Aliza Rozenberg, Ilan Yanuv, Erica L. Goodrich, Sabina A. Murphy, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P.H. Wilding, Ingrid A.M. Gause-Nilsson, Martin Fredriksson, Peter A. Johansson, Anna Maria Langkilde, Marc S. Sabatine, Itamar Raz

Diabetes Care 2020;43(2):468–475

DOI: https://doi.org/10.2337/dc19-1476

Published: 16 December 2019

View article

Includes: Supplementary data

Journal Articles

The Effect of Liquid Meal Replacements on Cardiometabolic Risk Factors in Overweight/Obese Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Jarvis C. Noronha, Stephanie K. Nishi, Catherine R. Braunstein, Tauseef A. Khan, Sonia Blanco Mejia, Cyril W.C. Kendall, Hana Kahleová, Dario Rahelić, Jordi Salas-Salvadó, Lawrence A. Leiter, John L. Sievenpiper

Diabetes Care 2019;42(5):767–776

DOI: https://doi.org/10.2337/dc18-2270

Published: 28 March 2019

View article

Includes: Supplementary data

Journal Articles

Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial

Lawrence A. Leiter, Hwee Teoh, David Kallend, R. Scott Wright, Ulf Landmesser, Peter L.J. Wijngaard, John J.P. Kastelein, Kausik K. Ray

Diabetes Care 2019;42(1):173–176

DOI: https://doi.org/10.2337/dc18-1491

Published: 28 November 2018

View article

Includes: Supplementary data

Journal Articles

Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors’ Expert Forum

William T. Cefalu, Sanjay Kaul, Hertzel C. Gerstein, Rury R. Holman, Bernard Zinman, Jay S. Skyler, Jennifer B. Green, John B. Buse, Silvio E. Inzucchi, Lawrence A. Leiter, Itamar Raz, Julio Rosenstock, Matthew C. Riddle

Diabetes Care 2018;41(1):14–31

DOI: https://doi.org/10.2337/dci17-0057

Published: 11 December 2017

View article

Includes: Supplementary data

Journal Articles

Dapagliflozin’s Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension

William T. Cefalu, Lawrence A. Leiter, Tjerk W.A. de Bruin, Ingrid Gause-Nilsson, Jennifer Sugg, Shamik J. Parikh

Diabetes Care 2015;38(7):1218–1227

DOI: https://doi.org/10.2337/dc14-0315

Published: 07 April 2015

View article

Includes: Supplementary data

Journal Articles

Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial

Lawrence A. Leiter, Hwee Teoh, Eugene Braunwald, Ofri Mosenzon, Avivit Cahn, K.M. Prasanna Kumar, Alena Smahelova, Boaz Hirshberg, Christina Stahre, Robert Frederich, Francois Bonnici, Benjamin M. Scirica, Deepak L. Bhatt, Itamar Raz, for the SAVOR-TIMI 53 Steering Committee and Investigators

Diabetes Care 2015;38(6):1145–1153

DOI: https://doi.org/10.2337/dc14-2868

Published: 10 March 2015

View article

Includes: Supplementary data

Journal Articles

Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial

Jacob A. Udell, Deepak L. Bhatt, Eugene Braunwald, Matthew A. Cavender, Ofri Mosenzon, Ph. Gabriel Steg, Jaime A. Davidson, Jose C. Nicolau, Ramon Corbalan, Boaz Hirshberg, Robert Frederich, KyungAh Im, Amarachi A. Umez-Eronini, Ping He, Darren K. McGuire, Lawrence A. Leiter, Itamar Raz, Benjamin M. Scirica

Diabetes Care 2015;38(4):696–705

DOI: https://doi.org/10.2337/dc14-1850

Published: 31 December 2014

View article

Includes: Supplementary data

Journal Articles

Efficacy and Safety of the Once-Weekly GLP-1 Receptor Agonist Albiglutide Versus Sitagliptin in Patients With Type 2 Diabetes and Renal Impairment: A Randomized Phase III Study

Lawrence A. Leiter, Molly C. Carr, Murray Stewart, Angela Jones-Leone, Rhona Scott, Fred Yang, Yehuda Handelsman

Diabetes Care 2014;37(10):2723–2730

DOI: https://doi.org/10.2337/dc13-2855

Published: 10 September 2014

View article

Includes: Supplementary data

Journal Articles

Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study

Lawrence A. Leiter, Kun-Ho Yoon, Pablo Arias, Gisle Langslet, John Xie, Dainius A. Balis, Dawn Millington, Frank Vercruysse, William Canovatchel, Gary Meininger

Diabetes Care 2015;38(3):355–364

DOI: https://doi.org/10.2337/dc13-2762

Published: 09 September 2014

View article

Includes: Supplementary data

Journal Articles

Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro

Julio Rosenstock, Vivian A. Fonseca, Jorge L. Gross, Robert E. Ratner, Bo Ahrén, Francis C.C. Chow, Fred Yang, Diane Miller, Susan L. Johnson, Murray W. Stewart, Lawrence A. Leiter

Diabetes Care 2014;37(8):2317–2325

DOI: https://doi.org/10.2337/dc14-0001

Published: 12 July 2014

View article

Includes: Supplementary data

Journal Articles

Effect of Lowering the Glycemic Load With Canola Oil on Glycemic Control and Cardiovascular Risk Factors: A Randomized Controlled Trial

Diabetes Care 2014;37(7):1806–1814

DOI: https://doi.org/10.2337/dc13-2990

Published: 12 June 2014

View article

Includes: Supplementary data

Journal Articles

Paradoxical Reduction in HDL-C With Fenofibrate and Thiazolidinedione Therapy in Type 2 Diabetes: The ACCORD Lipid Trial

Peter E. Linz, Laura C. Lovato, Robert P. Byington, Patrick J. O’Connor, Lawrence A. Leiter, Daniel Weiss, Rex W. Force, John R. Crouse, Faramarz Ismail-Beigi, Debra L. Simmons, Vasilios Papademetriou, Henry N. Ginsberg, Marshall B. Elam

Diabetes Care 2014;37(3):686–693

DOI: https://doi.org/10.2337/dc13-0790

Published: 11 February 2014

View article

Includes: Supplementary data

NARROW

Relation of Change or Substitution of Low- and No-Calorie Sweetened Beverages With Cardiometabolic Outcomes: A Systematic Review and Meta-analysis of Prospective Cohort Studies

Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58

Association of Baseline HbA_1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58

A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58

Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58

A Lesson From 2020: Public Health Matters for Both COVID-19 and Diabetes

Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease

Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study

The Effect of Liquid Meal Replacements on Cardiometabolic Risk Factors in Overweight/Obese Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial

Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors’ Expert Forum

Dapagliflozin’s Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension

Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial

Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial

Efficacy and Safety of the Once-Weekly GLP-1 Receptor Agonist Albiglutide Versus Sitagliptin in Patients With Type 2 Diabetes and Renal Impairment: A Randomized Phase III Study

Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study

Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro

Effect of Lowering the Glycemic Load With Canola Oil on Glycemic Control and Cardiovascular Risk Factors: A Randomized Controlled Trial

Paradoxical Reduction in HDL-C With Fenofibrate and Thiazolidinedione Therapy in Type 2 Diabetes: The ACCORD Lipid Trial

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

This Feature Is Available To Subscribers Only